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PERSPECTIVE

Toward refining Alzheimer’s disease into
overlapping subgroups
Erin R. Hascup1

Kevin N. Hascup1,2

1

Department of Neurology, Center for
Alzheimer’s Disease and Related Disorders,
Neurosciences Institute, Department of
Pharmacology, Springfield, Illinois, USA

2

Department of Medical Microbiology,
Immunology, and Cell Biology, Southern
Illinois University School of Medicine,
Springfield, Illinois, USA

Abstract
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized
by progressive anterograde amnesia, cerebral atrophy, and eventual death. Current
treatment has limited efficacy and cannot decelerate the disease progression. Clinical
trials targeting the removal of the neuropathological hallmarks of AD, including accumulation of amyloid plaques or neurofibrillary tangles, have failed to modify disease
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progression. Without new or innovative hypotheses, AD is poised to become a public
health crisis within this decade. We present an alternative hypothesis—that AD is the
result of multiple interrelated causalities. The intention of this manuscript is to initiate
a discussion regarding these multiple causalities and their overlapping similarities.
The idea of creating subgroups allows for better identification of biomarkers across
a narrower patient population for improved pharmacotherapeutic opportunities. The
interrelatedness of many of these proposed subgroups indicates the complexity of this
disorder. However, it also supports that no one single factor may initiate the cascade
of events.
KEYWORDS

cellular senescence, hyperexcitable neuronal networks, metabolic syndrome, mitochondrial cascade hypothesis, sleep disturbances, traumatic brain injury, two-hit vascular hypothesis

1

INTRODUCTION

continues to be incurable and teeters on the precipice of becoming a
public health disaster.

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder

The primary neuropathological hallmarks of AD include extracellu-

characterized by progressive anterograde amnesia, neuronal loss,

lar plaques composed of aggregated amyloid beta (Aβ) and intracellular

cerebral atrophy, and eventual death. Currently AD is the sixth leading

neurofibrillary tangles formed from hyperphosphorylated tau protein.

cause of death in the United States, with an estimated 5.8 million

To date, these biomarkers are used to indicate disease progression and

Americans diagnosed, posing a severe socioeconomic impact. Available

post-mortem AD confirmation. However, there is ongoing debate as

pharmacotherapeutic options target cholinesterase inhibitors and

to which proteinopathy precipitates the neuropathological changes

partial antagonism of the N-methyl-D-aspartate (NMDA) receptors;

that culminate in clinical manifestation of dementia and AD diagnosis.

these treatments have limited efficacy, are symptomatic, and do not

Arguments for Aβ, tauopathies, and synergistic effects have been

decelerate disease progression. Despite decades of attempted clinical

proposed as the underlying mechanism that initiates the pathological

trials to bring novel, disease-modifying compounds to market, AD

chain reaction of events. However, clinical trials designed to target
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various mechanisms involved in accumulation and aggregation of
these misfolded proteins have been unsuccessful at slowing disease

RESEARCH IN CONTEXT

progression. These failures are attributed to multiple factors including
poor trial design, entry criteria, retention rates, clinical endpoints, and

1. Systematic review: The authors reviewed the literature
using PubMed and Google Scholar. Although genetic and

disease stage selection.1 After all, what good is clearing the brain of

environmental risk factors for Alzheimer’s disease (AD)

misfolded proteins if neuronal damage is already too pronounced to

are well explored in the literature, to-date, no disease-

have a pro-cognitive impact? This has driven the need to reclassify

modifying therapies have been developed. This has led

AD based on available cerebral spinal fluid (CSF) and neuroimaging
biomarkers for earlier

diagnosis,2

the authors to discuss these in terms of individual, but

with the hopes of providing better

potentially overlapping, causalities that trigger the cog-

therapeutic outcomes.

nitive and functional decline observed in AD. All relevant

The inability to find a biomarker (or multiple biomarkers) that accu-

citations are appropriately cited.

rately predicts disease manifestation may be flawed due to the comorbidity of the disease. This article presents an alternative hypothesis

2. Interpretation: Our article serves as a discussion for
elucidating AD subtypes based on environmental fac-

regarding our initial presumptions of AD. That multiple, yet potentially

tors such as blood-brain barrier disruption, metabolic

overlapping, causalities contribute to the neuropathological changes,

syndrome, mitochondrial dysfunction, traumatic brain

which trigger the cognitive and functional decline observed in AD. This

injury, hyperactive neuronal networks, cellular senes-

article is intended to start discussion of the major individualistic com-

cence, sleep disturbances, and microbial infiltration in

ponents rather than an exhaustive criterion or description of each pos-

conjunction with the involvement of early and late-onset

sible subgroup. Eventually, large data set analysis will be needed from

AD genes.

already existing databases (including the World Wide AD Neuroimaging Initiative, National Institute on Aging Genetics of AD Data Storage,

3. Future directions: Creating AD subgroups allows for
biomarker identification across a narrower patient popu-

National Alzheimer’s Coordinating Center, and the Global Alzheimer’s

lation for improved pharmacotherapeutic opportunities.

Association Interactive Network, to name a few) for identification and

The interrelatedness of many of these proposed sub-

confirmation of novel subgroups in a manner similar to recent research
into

diabetes.3

groups indicates combination therapeutic approaches are

Neuropathological variation already indicates multi-

warranted.

ple comorbidities exist that may mimic AD. However, thorough clinical and epidemiological analysis can elucidate subgroups or even distinct disease states such as Limbic-Predominant Age-Related TDP-43
Encephalopathy. Creating subgroups allows for better identification

significantly enhanced our understanding of AD leading to the amyloid

of biomarkers across a narrower patient population for individualized

cascade hypothesis, which states that Aβ accumulation causes synap-

treatment regimens.

tic dysfunction, formation of neurofibrillary tangles from hyperphosphorylated tau protein, and neuronal loss. However, these autosomal
dominant mutations may account for only a small percentage of EOAD

1.1

Genetic subgroups

cases, with unidentified autosomal recessive traits accounting for the
remainder.

1.1.1

Early onset genetic subgroups for AD

Age is the primary risk factor for developing AD, with 65 years of age

1.1.2

Late-onset genetic subgroups for AD

is designated as the cutoff that defines early onset AD (EOAD) versus late-onset AD (LOAD). Current estimates indicate that 2% to 10%

Recent genome-wide association studies (GWASs) have identified at

of all AD cases are EOAD and that these patients first present with

least 21 genetic loci that increase the risk for LOAD.5 However, for

observable symptoms between 30 and 65 years or age.4

In addition to

a majority of these loci, the biological importance with regard to dis-

memory impairments, these EOAD patients also include non-cognitive

ease pathogenesis is relatively unknown. As such, this article focuses

symptoms such as aphasia and visual dysfunctions. Genetic studies of

on genes that have established mechanisms contributing to LOAD.

patients with EOAD have identified several autosomal dominant mutations including amyloid precursor protein (APP), presenilin 1 (PSEN1),
and presenilin 2 (PSEN2). Normal, non-amyloidogenic APP process-

1.1.3

Apolipoprotein E

ing occurs by sequential cleavage of β- then γ-secretase resulting in
Aβ peptide of up to 40 base pairs in length. Mutations in PSEN1 or

Apolipoprotein E (apoE) is a glycoprotein involved in cholesterol trans-

PSEN2, the catalytic region of γ-secretase, creates Aβ peptides with

port, the gene of which in humans exists as three polymorphic alleles

42 residues.4 Referred to as the amyloidogenic pathway, these longer

(ε2, ε3, and ε4). The APOE ε4 allele is the major gene with semi-dominant

Aβ peptides are prone to aggregation that is responsible for the diffuse

inheritance that increases the odds ratio of developing AD throughout

neuritic plaques observed in AD. Identification of these mutations has

an individual’s lifetime. This gene is the second biggest risk factor
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for developing AD, only behind aging, and has sex (female > male)

anti-inflammatory responses by suppressing tumor necrosis factor

and copy number (homozygous > heterozygous) attributes. Although

(TNF) and interleukin (IL)-6.12 Arginine-to-histidine TREM2 point-

APOE ε4 is also associated with EOAD, this is at a much lower ratio

mutation variants lead to impaired phospholipid binding, Aβ plaque

than in individuals older than 60 years of age and observed more

accumulation, tau hyperphosphorylation, neuroinflammation, and

frequently in patients who have a positive family history of AD.

neuronal damage indicating proper microglial function is important for

Several mechanisms explain this increased incidence of AD. In the

preventing AD pathology.

central nervous system (CNS), apoE is the primary protein responsible for triglyceride and cholesterol transport, which is necessary
for maintaining the lipid membranes of nervous tissue as well as

1.2

Environmental subgroups

axonal myelination. The APOE ε4 allele is less efficient at transporting these fatty acids, thereby altering glucose transporter function

1.2.1

Traumatic brain injury (TBI)

leading to metabolic dysregulation.6 In addition, apoE is an Aβ
chaperone, but the isoforms differ in their binding affinities. The APOE

TBI is the result of a sudden impact to the head causing damage to the

ε2 and ε3 alleles facilitate Aβ clearance across the blood–brain barrier

brain and potentially loss of consciousness (LOC). Motor vehicle acci-

(BBB) through low-density lipoprotein receptor-related protein 1

dents, sports, combat zone injuries, and falls are the major contributors

(LRP1), whereas the ε4 facilitates oligomerization and deposition

to TBI, which commonly involve the frontal and temporal lobes.13 The

With regard to tau pathology, apoE ε3 binding

pathobiology of TBI is often divided into focal or diffuse injuries; how-

can prevent hyperphosphorylation, unlike ε4 carriers that have higher

ever, most moderate and severe insults involve combinatorial effects.

total tau, phosphorylated tau, and tau/Aβ42 ratios. These multifactorial

The initial insult results in edema and swelling, followed by ischemia,

phenotypes may confer synergistic effects that are detrimental over

excitotoxicity, and reactive gliosis that triggers numerous apoptotic

time.

and necrotic cellular pathways leading to neuronal loss.13 But, despite

rather than

clearance.7

the numerous documented occurrences of TBI, clinical studies to examine this causal relationship for later-life dementia have produced dis-

1.1.4
Translocase of outer mitochondrial
membrane 40

cordant results. Several studies support a history of TBI contributing

Translocase of outer mitochondrial membrane 40 (TOMM40) gene is

sistent reporting of TBI severity and self-reported LOC may undermine

in linkage disequilibrium with APOE. A poly-T polymorphism at intron

the AD predictive value of these findings. Additional factors such as the

6 of the TOMM40 gene is associated with increased risk and onset

number of injuries, inter-injury interval, and age of occurrence may also

of AD that is APOE-independent.8 However, others have shown that

increase the dementia risk,16 while adding to the complexity of inter-

TOMM40 poly-T associations with LOAD-related phenotypes are a

preting the results.

to dementia and AD later in life,14 whereas others have shown no
association.15 However, methodological considerations, such as incon-

result of single nucleotide polymorphisms of the APOE allele located

The complexity of TBI may account for several different mechanisms

in proximity to the TOMM40 gene on chromosome 19.9 These dis-

associated with AD development. Neuronal loss is believed to under-

parate findings may be due to the length of the Poly-T polymorphism,

lie the long-term effects on cognitive dysfunction and worse functional

the AD phenotype being assessed, and the individual’s age at the time

outcome in the geriatric population.17 Individuals with a genetic pre-

of assessment. This gene codes for the Tom40 protein essential for

disposition for AD may experience a synergistic effect from TBI. For

translocation of nuclear-encoded proteins into the mitochondria. This

example, individuals with the APOE ε4 allele and a history of TBI had a

results in mitochondrial dysfunction, oxidative stress, and bioenerget-

significantly increased risk for developing AD compared to those with-

ics deficits that cause apoptotic cell death.

out head injuries,18 thereby supporting a reduced resiliency. Because
the ε4 allele is not as efficient at transporting lipids and triglycerides,
axonal remyelination would be reduced following TBI, which may initi-

1.1.5
Triggering receptors expressed on
myeloid cells

ate long-term neurodegenerative processes, and the susceptibility of
tau and amyloid accumulation in ε4 genotypes may potentiate these
effects.

Triggering receptors expressed on myeloid cells (TREMs) are trans-

Athletic sports with the potential for repeated head trauma are

membrane glycoproteins responsible for regulation of innate immune

known to develop adverse cerebral proteinopathies, including neu-

resistance. TREM2 homozygous loss-of-function mutations are

rofibrillary tangles (and occasionally amyloid plaques), in what has now

associated Nasu-Hakola disease, which is characterized by osteo-

been documented as chronic traumatic encephalopathy. These pro-

clast abnormalities and dementia. In addition, genomic sequencing

teinopathies have also been observed throughout the brain, years after

of AD patients indicates that heterozygous TREM2 mutations are

a single incidence of TBI.19 Although the mechanism for this accumula-

risk factors for

LOAD.10

In the CNS, Trem2 is exclusively found on

tion is the subject of intense research, the damaged axons may provide

microglia and binds lipoproteins, Aβ, and apoE with similar affinities

a chronic source for misfolded proteins. APP is known to accumulate in

for all three

isoforms.11

Activation of the TREM2 receptor results in

degenerating axons, whereas tau hyperphosphorylation could be the
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result of mechanical stress on microtubules.20 Overtime, the diffuse

pronounced in cognitively impaired individuals and before neuronal

deposition patterns could be attributed to prion-like spread of these

atrophy.24 Pericyte loss is a contributing factor to BBB breakdown that

proteinopathies.21

has been observed in both MCI24 and AD post-mortem tissue. This

BBB damage after TBI causes acute and long-term cerebrovascu-

allows blood-derived neurotoxic species including hemoglobin, plas-

lar dysfunction that may also be a precipitating factor in the etiol-

min, thrombin, and fibrin to enter the CNS, causing vascular-mediated

ogy of AD. Oligomeric Aβ and hyperphosphorylated tau have been

secondary neuronal degeneration. Vascular damage also reduces Aβ

found surrounding damaged cerebral microvessels in post-mortem TBI

clearance from the interstitial fluid through LRP1, which subsequently

patients.22 The reasons for this accumulation are largely unknown, but

amplifies pericyte loss and microvasculature lesions.30 The accumula-

the damaged microvasculature may prevent adequate

clearance.23

In

tion of amyloid deposits along cerebral microvasculature, called cere-

addition, amyloid and/or tau accumulation have been shown to disrupt

bral amyloid angiopathy, is a pathological feature of AD and is believed

the neurovascular unit (discussed below) independent of TBI. A feed-

to exacerbate cognitive decline.31 The combination of amyloid accu-

forward mechanism might result whereby accumulation of misfolded

mulation and pericyte loss causes tau hyperphosphorylation and sub-

proteins surrounding damaged microvasculature cause further deteri-

sequent neuronal damage.30

oration and aggregation.23 Regardless, further research is needed to
elucidate the causality of TBI on initiation of dementia and AD.

In addition, the underlying vascular similarities of several midlife
AD risk factors (obesity, hypertension, and diabetes) have led to the
two-hit vascular hypothesis of AD.32 Based on this hypothesis, vascular risk factors (hit 1) cause BBB disruption, hypoperfusion, and

1.2.2

Blood–brain barrier disruption

decreased neurovascular coupling, leading to early neuronal dysfunction. The resulting increase in amyloid accumulation (hit 2) propagates

The neurovascular unit of the BBB is composed of smooth mus-

AD progression by aggravating BBB dysfunction, accelerating amyloid

cle and endothelial cells, astrocytic end feet, neurons, and pericytes

and tau deposition, and amplifying the neurodegeneration and subse-

that form gap and tight junctions to create a semipermeable mem-

quent cognitive decline.

brane. This membrane maintains the CNS extracellular fluid while
preventing neurotoxic compounds and microbial agents from entering the CNS through the bloodstream, which also adds to the com-

1.2.3

Metabolic syndrome and insulin resistance

plexity of designing CNS therapeutics. Selective transport of essential macromolecules (glucose, cholesterol, etc) occurs by transcyto-

Metabolic syndrome (MetS) refers to multiple metabolic disturbances

sis that maintains neurovascular coupling, hemodynamic responses to

including hyperglycemia, hypercholestrolemia, dyslipidemia, adiposity,

support energy demands during neuronal activity. Aging is associated

and insulin resistance, which increase the risk of cardiovascular disease

with a modest decline in cerebral blood flow and BBB breakdown to

and type 2 diabetes mellitus (T2DM). Over the past several decades the

the limbic and associative cortices.24 This gradual cerebral hypoper-

prevalence of MetS has risen steadily throughout the United States.

fusion reduces the supply of energy substrates that are important for

These metabolic dysregulations are often attributed to overnutrition

maintaining these neuronal networks25 while simultaneously impair-

and sedentary lifestyles. Furthermore, the natural decline of basal

ing clearance of neurotoxic proteinopathies. Not surprisingly, vascular

metabolic rate, compounded with lifestyle choices, increases the inci-

dysfunction is observed in numerous neurodegenerative disorders, and

dence of MetS during aging. More than half of all adults 70 years of

may be the instigating factor precipitating AD progression.

age or older meet the criteria for this disorder.33 Although the vascu-

Neuronal activity and the subsequent metabolic demands regulate

lar risk factors associated with MetS and their contribution to AD eti-

cerebral blood flow. Individuals with MCI or AD display resting cerebral

ology has been discussed previously, insulin resistance is hypothesized

hypoperfusion that gradually progresses with disease severity and may

to be a separate contributor to disease initiation. The co-morbidity

be present before overt signs of cognitive

decline.26

In mouse models

of vascular and insulin signaling pathways in MetS makes it difficult

of AD pathology, transient hypoperfusion causes long-lasting increases

to discriminate their causal effects on AD pathogenesis because both

to tau hyperphosphorylation and enhanced expression of β-secretase

are linked to hippocampal dysfunction. However, imaging analysis sup-

that causes elevated amyloid levels.27 Imaging studies in humans, how-

ports region-specific effects, whereby the dentate gyrus is vulnerable

ever, support a role for amyloid deposition, causing rather than being a

to hypoglycemia related to insulin resistance, but the CA1 and subicu-

result of cerebral hypoperfusion. The level of amyloid deposition was

lum show more dysfunction from hypoperfusion related to vascular

associated with cerebral blood flow reductions that progressed as a

abnormalities.34

function of disease severity.28

Accordingly, those with genetic risk fac-

Observational, longitudinal, and prospective studies have shown

tors associated with amyloid accumulation may be at a greater risk

that insulin resistance and T2DM during midlife are associated with

for vascular abnormalities. The limited clinical studies warrant further

an increased risk for developing dementia and AD later in life.16 And

investigation.

recently, a genetic association between fasting glucose, insulin lev-

Disruption of the BBB increases vascular permeability and hypop-

els, and AD has been demonstrated.35 Insulin, and the structurally

erfusion, resulting in perturbed neurovascular coupling.29 Decline of

analogous insulin-like growth factor 1, are locally produced in the

BBB integrity is observed in the aging hippocampus first, which is more

brain where they can act upon their corresponding receptors located
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throughout the cortex, hippocampus, and hypothalamus. Receptor

antioxidant mechanisms. At low concentrations, ROS is important for

activation has been shown to regulate glucose uptake, promote

synaptic plasticity involved with memory formation and consolidation,

synaptic plasticity, improve cognition, and modulate pro-inflammatory

but excessive production of ROS can lead to oxidative stress and lipid

cytokines that are important for healthy aging. Conversely, impaired

peroxidation that can develop into pathological conditions.

insulin signaling accelerates aging and has been demonstrated in the

The metabolic demands placed upon neuronal networks are a rea-

hippocampus of AD patients. Based on this cerebral insulin resistance,

son why the brain utilizes 20% to 25% of total body glucose. A gradual

some groups have postulated that AD is a third subtype of diabetes.36

decline in cerebral energy utilization with an increase in chronic oxida-

Through separate pathways, insulin resistance causes accumula-

tive stress is observed with normal aging.42 However, neuroimaging

tion of both amyloid and tau pathology. Insulin signaling promotes

with [18 F]fluorodeoxyglucose positron emission tomography (FDG-

nonamyloidogenic processing of APP while subsequently increas-

PET) indicates that hypometabolism is worse in AD patients compared

ing insulin degrading enzyme (IDE) that cleaves Aβ. But dysfunc-

to age-matched controls, is observable before cognitive deficits, and

tional insulin signaling promotes amyloid accumulation by decreas-

is a sensitive measurement of AD progression.43 Multiple factors can

ing both the expression of IDE and its affinity to cleave monomeric

contribute to cerebral hypometabolism including reduced glucose

Aβ42 ,37 causing its aggregation and accumulation. Furthermore, insulin

transporter number or function, BBB disruption, and/or mitochondrial

resistance increases tau hyperphosphorylation through activation of

dysfunction, which makes elucidating the primary cause difficult.

glycogen synthase kinase 3β and inhibition of AMP-activated pro-

However, a maternal family history of AD predisposes individuals to

tein kinase-mediated tau dephosphorylation. Hyperphosphorylated

hypometabolism as indicated by FDG-PET.44 Because mitochondrial

tau also aggravates insulin resistance by accumulating insulin as insolu-

DNA is passed along maternally, this supports a primary role for

ble oligomers inside neurons.38

Accumulation of these proteinopathies

mitochondrial dysfunction as the instigating process in AD, which has

increases glial pro-inflammatory cytokines (TNFα, IL-6, and IL-1β),

been coined the “mitochondrial cascade hypothesis.”45 For example,

which cause phosphorylation of serine on insulin receptor substrate

ATP can both prevent protein aggregation and dissolve previously

1, blocking insulin signaling.39 Furthermore, peripheral inflammation

formed aggregates.46 The aggregation of amyloid and tau may be

caused by adiposity can exacerbate pro-inflammatory cytokines that

linked directly to decreased ATP production as a result of mitochon-

can readily cross the BBB irrespective of its integrity having been com-

drial dysfunction. Mitochondrial import receptors can interact with

promised by vascular risk factors. This creates a vicious feed-forward

misfolded protein aggregates, leading to their subsequent import

cycle propagating AD pathology and neurodegeneration.
In addition to propagating AD pathology, cerebral insulin insensitivity alters glucose metabolism. Compared to cognitively normal control

and degradation by proteases.47 A decline in mitochondrial function
would prevent protease degradation and lead to the accumulation and
aggregation of misfolded proteins observed in AD.

patients, post-mortem analysis of AD patients have reduced glycolytic

These mitochondrial disruptions may initially occur at the level of

flux despite elevated glucose levels in CNS tissue.40 Several factors

individual neurons or synapses before more global effects occur. A

may contribute to the elevated glucose levels including reduced

neuron with impaired mitochondria has reduced energy production

expression,40

defective insulin receptor

and may up-regulate oxidative phosphorylation as a compensatory

signaling, and reduced CNS insulin levels.39 Irrespective of the mode

mechanism in a process referred to as the inverse Warburg effect.48

of resistance, the overall net effect is reduced utilization of available

This “unhealthy” neuron pulls additional energy substrates (glucose

energy substrates that decreases mitochondrial bioenergetics, which

and lactate) from the surrounding glia, while simultaneously increas-

are important for maintaining functional neuronal networks. Selective

ing the production of ROS. These two factors cause nutrient deple-

CNS insulin increases can be achieved by intranasal delivery, which has

tion and oxidant stress in “healthy” neurons, thereby leading to addi-

pro-cognitive effects in healthy, MCI, and AD patients that may also

tional mitochondrial dysfunction that precipitates their conversion to

attenuate classical AD proteinopathies.41

an unhealthy phenotype. Over time, this can cause neuronal loss and

glucose transporter surface

lead to the cognitive impairments observed in AD. Because this process
is postulated to begin with individual mitochondrial deficits, it has not

1.2.4

Mitochondrial-bioenergetic deficits

been tested experimentally.

Mitochondrial organelles maintain numerous cellular functions that
are critical for healthy aging, including energy metabolism, calcium

1.2.5

Hyperactive neuronal networks

homeostasis, apoptosis, lipid metabolism, redox signaling, stem cell
fate, and cellular senescence. These processes can vary across cell

One of the earliest preclinical symptoms associated with AD is hip-

type. Although astrocytes utilize glycolytic pathways to produce

pocampal epileptiform discharges indicative of hyperactive neuronal

adenosine triphosphate (ATP), neurons rely heavily on oxidative

networks.49 These hyperactive neuronal networks have been observed

phosphorylation for its generation to help maintain neurotransmitter

years prior to onset of cognitive impairment and can progress in sever-

synthesis and uptake, resting membrane potential, and synaptic

ity with accumulation of either Aβ or tau.50 However, it is uncertain if

plasticity. A byproduct of oxidative phosphorylation is the formation

these effects are dependent upon abnormal AD-specific protein accu-

of reactive oxygen species (ROS), the levels of which are modulated by

mulation or contribute to spreading the pathology. Endogenous Aβ
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was shown to increase the release probability at excitatory synapses51
as well as stimulate synaptic glutamate

release.52

particularly impact the CA1 pyramidal neurons and could underlie the

But, transsynaptic

initial anterograde amnesia observed in AD. A better understanding

signaling has also been implicated in the spreading of both tau and

and interpretation of CNS senescent cell types and their resulting

Aβ pathologies.21 In addition, hyperactive neuronal networks require

phenotypes will help to elucidate a role in AD.

considerably more energy substrates for ATP production to maintain
both neurotransmitter synthesis and the resting membrane potential. To maintain the energy substrates, focal changes in blood flow

1.2.7

Microbial infiltration

surrounding the hyperexcitable neuronal networks are required that
results in alterations to neurovascular coupling and has the potential

An infectious origin to the etiology of AD has been marred with con-

to propagate seizure activity into other cortical areas.

flicting results. Previous post-mortem analysis of AD CNS tissue does

The underlying cause of the hyperactive neuronal networks could

not indicate a microbial connection. But more recent data support

be attributed to excitatory/inhibitory imbalance that can cause mem-

the presence of viral, bacterial, and fungal microbes in post-mortem

ory impairments with age.53 Either an increase in the amount of

brain tissue of AD patients.57 These discrepant findings are oftentimes

glutamate, a decrease in γ-aminobutyric acid, or both, would result in a

attributed to methodological considerations, including tissue region

net overall increase in local environments of tonic levels of glutamate.

analyzed and fixed vs frozen preservation methods, with the latter

These increased tonic levels of glutamate are thought to underlie

providing higher quality DNA samples. The strongest microbial case

the initial onset of cognitive impairment because the persistent acti-

involves herpes simplex virus type 1 (HSV1) in combination with APOE

vation at postsynaptic receptors dampens physiologically relevant

ε4 carriers.58 Meta-analysis between spirochetal bacteria or Chlamy-

signaling.54

As such, this may explain why memantine, a partial NMDA

dophila pneumoniae indicates a respective 10- and 5-fold increased

antagonist, has shown pro-cognitive effects in AD patients. Over time,

association with AD brains compared to control brains.59 At present,

if this excitatory/inhibitory imbalance is not corrected, glutamate

though, more questions than answers exist, including route of infil-

levels may cross a threshold and become excitotoxic and contribute to

tration and active residence. As mentioned previously, disruptions of

neuronal loss, cortical atrophy, cognitive decline, and eventual death.

the brain microvasculature enable toxic cells and microbial agents to
enter the brain causing inflammatory and immune responses that initiate neurodegenerative processes. Although these microbial species

1.2.6

Cellular senescence

have also been observed in the blood, it is unknown if they actively participate to BBB deterioration. Once inside the CNS, are these microbes

Cellular senescence is characterized by a permanently arrested cell

dormant or active participants in known AD pathology? Because the

cycle that is no longer responsive to differentiation and apoptotic

majority of microbes are associated with amyloid plaques,57,58 this

signaling processes, yet are still metabolically active. Senescent cells

may support an active role in facilitating amyloid accumulation. Even

accumulate in multiple mitotic tissue types as a result of various

if microbes take up dormant CNS residence, their potential to chroni-

stressors, and they have become a hallmark response of natural aging.

cally activate pro-inflammatory cytokines can have deleterious effects

Once cells undergo senescence, they begin to secrete numerous

on pathobiology. Regardless, more research is needed to elucidate a

pro-inflammatory cytokines and chemokines in a process referred to

potential microbial cause to initiating AD pathology, particularly given

as senescence-associated secretory phenotype, which has additional

the neurological manifestations in patients infected with severe acute

deleterious consequences in both neighboring and remote cells.

respiratory syndrome coronavirus 2.60

Because cellular senescence is a result of the aging process, this has
led to the hypothesis of a causative nature in AD. Because neurons
exist in a post-mitotic state, it is difficult to definitively determine

1.2.8

Sleep disturbances

if they can undergo a senescent phenotype. However, other cell
types that are essential for supporting neuronal function can become

Over the past several decades, the number of adults and children

senescent. Astroglia, important for regulating synaptic transmission,

experiencing chronic sleep insufficiency is steadily rising and has been

BBB integrity, and neuronal metabolism, accumulate in the aged brain

attributed to increased working and screen time hours. Quality sleep

and in higher abundance in the brains of patients with AD. Senescent

aids in memory consolidation, whereas sleep deprivation is known to

astrocytes have reduced expression of excitatory amino acid trans-

reduce cognitive performance and increase the risk for developing

porters, resulting in decreased synaptic glutamate clearance.55 The

MetS. Several meta-analyses link disrupted sleep patterns to the devel-

reduced glutamate clearance can cause hyperexcitable neuronal net-

opment of cognitive decline and AD.61 In particular, sleep-disordered

works that may, over time, create an excitotoxic environment leading

breathing and insomnia have been shown to predict cognitive decline

to neuronal atrophy. In addition, oligodendroglial progenitor cells,

and may serve as a potential biomarker.62 Restful sleep increases

which are responsible for myelinating neuronal axons, also undergo

the interstitial space, allowing for clearance of cellular activity waste

senescent phenotypes in AD brains, particularly surrounding amyloid

products through CSF exchange referred to as the glymphatic system.

plaques.56 Insufficient myelination reduces the membrane resis-

Even a single night of sleep deprivation can cause Aβ accumulation.63

tance, thereby leading to loss of action potential velocity. This would

Furthermore, sleep disturbances can limit CSF transfer of apoE into
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the brain to help maintain axonal myelination, synaptic plasticity, and
cognition.64

However, a better understanding is needed to determine

whether sleep disturbances contribute to or is a result of dementia.

TA B L E 1

AD subgroup diagnostics determinants

AD subgroup

Diagnostic determinates

Genetic
APP

Genetic testing, amyloid positron emission
tomography, CSF amyloid levels

PS1/PS2

Genetic testing, amyloid positron emission
tomography, CSF amyloid levels

APOE ε4

Genetic testing, FDG-PET,
blood-oxygen-level dependent functional
magnetic resonance imaging, CSF lipid,
phosphorylated tau, and tau/Aβ42 levels

screenings, but provide only a subjective reference point with regard

TOMM40

Genetic testing, microRNAs

to the symptomatic degree of cognitive decline. Considering that

TREM2

Genetic testing, CSF phosphorylated tau
and tau/Aβ42 levels

1.3

Methods to refine AD subgroups

The majority of individuals diagnosed with AD present to a general
practitioner or specialist because of the concern of a caregiver who
notices memory and behavior differences. These patients typically
undergo a battery of low-cost and non-invasive neuropsychological

irreversible neuronal damage occurs decades prior to the onset of
neurobehavioral and neuropsychiatric symptoms, the ability to longitudinally detect subtle changes to the cerebral parenchyma and

Environmental

microvasculature are paramount for preclinical AD diagnosis. Table 1

Hyperactive
neuronal networks

Electroencephalography, functional
magnetic resonance imaging

outlines additional non-invasive and minimally invasive screening

Cellular senescence

microRNAs, FDG-PET

methods that may be beneficial to the refinement of these AD

Mitochondrial
dysfunction

TOMM40 genetic testing, electron
paramagnetic resonance imaging,
microRNAs

Metabolic syndrome

Hemoglobin A1c levels, fasting blood
glucose, hypertension, FDG-PET,
blood-oxygen-level dependent functional
magnetic resonance imaging, microRNAs

Blood–brain barrier
disruption

Magnetic resonance imaging, arterial spin
labeling magnetic resonance imaging,
blood-oxygen-level dependent functional
magnetic resonance imaging, dynamic
susceptibility contrast, single photon
emission computed tomography

Traumatic brain
injury

Prior history of concussions with loss of
consciousness, computerized
tomography, magnetic resonance imaging,
diffusion tensor imaging

Sleep disruption

Polysomnography, CSF for Aβ/APP
clearance, actigraphy,
electroencephalography

Microbial infiltration

Patient history, CSF

subgroups.
Genetic testing is a useful screening method for determining genes
associated with EOAD and LOAD, particularly in individuals with a
family history of AD. These are often inexpensive and some are available for in home genetic services. However, consideration is needed
with regard to the long-term psychological implications of knowing the
genetic predisposition for any disorder. Although genetic counseling
may be needed, an earlier diagnosis allows for implementation of riskreduction strategies.65 Once possible genetic markers have been elucidated, additional clinical utilities can help determine environmental
AD subgroups. A patient history is useful for determining prior TBI and
possible microbial infiltration. Because CSF is in direct contact with
the brain, a lumbar puncture can be used to monitor plaque accumulation (decreased Aβ42 CSF), neurofibrillary tangles (elevated phosphorylated tau CSF), and neuronal damage (elevated total tau CSF). When
coupled with advances in neuroimaging techniques, this can lead to further refinement for cerebral proteinopathy accumulation, neurovascular changes, and glucose metabolism. Monitoring brain activity with
electroencephalography could elucidate regions with hyperactive neuronal networks, while polysomnography can detect sleep disorders.
Unfortunately, these additional screening methods are both cumbersome and expensive. Accordingly, blood or plasma biomarker determination is the sought-after solution, but this is potentially hindered by

Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E gene;
APP, amyloid precursor protein; CSF, cerebral spinal fluid; FDG-PET,
[18 F]fluorodeoxyglucose positron emission tomography; PS1/2, presenilin
1 or 2; TOMM40, translocase of outer mitochondrial membrane 40 gene;
TREM2, triggering receptors expressed on myeloid cells gene2.

age-associated changes to the blood proteome. Identification of specific microRNAs may prove beneficial in subgroups with mitochondrial

article is to initiate a discussion regarding the multiple causalities that

dysfunction or senescent cell accumulation.

culminate in the anterograde amnesia and cerebral atrophy that the
field has grouped into a single disease entity—AD. The idea of creating
subgroups allows for better identification of biomarkers across a

2

CONCLUSIONS

narrower patient population for improved pharmacotherapeutic
opportunities. These biomarkers can then aid in designing appropriate

Despite decades of clinical trials, the AD field is not closer to bringing

preclinical models that more accurately recapitulate subgroup-specific

disease-modifying therapeutics to market. To improve therapeutic

disease pathologies for identification and testing of novel therapeutics.

outcome for the rapidly growing AD population, an ideological shift

The interrelatedness of many of these proposed subgroups indicates

regarding the interpretation of AD is needed. The intention of this

the complexity of this disorder as shown in Figure 1. However, it
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F I G U R E 1 Overlapping genetic and environmental subgroups. Genetic screening for determination of early and late-onset AD subgroups can
identify individuals at risk for developing dementia before symptoms appear. Individuals who screen positive can implement life-style
risk-reduction strategies that are known to have long-term pro-cognitive benefits. In addition, annual positron emission tomography (PET)
monitoring for accumulation of proteinopathies may provide therapeutic opportunities for health-span and lifespan extensions in these at-risk
individuals. Without readily identifiable biomarkers, environmental factors are more difficult to screen, thereby delaying a diagnoses until overt
signs of dementia are present. The environmental subgroups discussed are arranged adjacent to potentially overlapping pathologies. This
highlights environmental subgroups with possible comorbidities that may require multiple therapeutic strategies for individualized patient care.
Furthermore, genetic subgroup pathologies may exacerbate particular environmental subgroups as indicated by their inset symbol. AD,
Alzheimer’s disease; APOE, apolipoprotein E gene; APP, amyloid precursor protein; BBB, blood–brain barrier; MetS, metabolic syndrome; PS1/2,
presenilin 1 or 2; TBI, traumatic brain injury; TOMM40, translocase of outer mitochondrial membrane 40 gene; TREM2, triggering receptors
expressed on myeloid cells 2 gene

also supports that no one single factor may initiate the cascade of
events culminating in neurodegeneration and cognitive decline. As
such, combination therapeutic approaches may be warranted. Finally,

4.

longitudinal analysis as well as sexual dimorphisms associated with
each subgroup could further refine individualized treatment options.
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